Please ensure Javascript is enabled for purposes of website accessibility

If You Invested $10,000 in Moderna During the Coronavirus Market Crash, This Is How Much Money You'd Have Now

By David Jagielski - Updated Feb 16, 2021 at 1:13PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

And the stock may still be a good buy right now.

Moderna (MRNA -4.97%) has been one of the top growth stories of the past year. In just 12 months, its shares have skyrocketed more than 860%, blowing past the S&P 500 and its 16% gains during that time frame. If you had bought shares of the company during the coronavirus market crash last year, you would be sitting on an incredible profit today.

The company has made a name for itself thanks to the success of its COVID-19 vaccine, MRNA-1273. And what's exciting is that Moderna's stock has the potential to climb even higher. 

COVID-19 vaccine.

Image source: Getty Images.

In March 2020, Moderna's shares were trading at about $20

During the coronavirus market crash last year, Moderna's stock fell from just under $30 a share to less than $20. At that price, a $10,000 investment in the company would have given you approximately 500 shares.

Moderna was still in the early stages of working on a vaccine for COVID-19, and betting that it would be successful was still a big risk to take. After all, back then the company didn't have much of a track record -- or any approved drugs. Investors putting money in Moderna were taking on a lot of risk.

The risk would have paid off

At a price of about $184, that $10,000 investment would now be worth approximately $92,000. That's a terrific 820% return for holding on to a stock for less than a year. It's a great example of a high-risk, high-reward investment: If the company had failed to obtain emergency use authorization (EUA) for its MRNA-1273 vaccine candidate, the stock would have flopped.

When the U.S. Food and Drug Administration (FDA) gave Moderna's candidate the thumbs-up in December 2020, its shares had already reached highs of more than $170.

Is Moderna still a good buy?

The big question is how much higher the stock can go, and whether it's worth investing in Moderna right now. The company does have other drugs in its pipeline that could generate significant sales, including mRNA-1647, which is a vaccine for cytomegalovirus (a form of herpes). Management estimates this drug has the potential to generate up to $5 billion in annual revenue at its peak. There's also its Zika vaccine, which could become a "several hundred-million-dollar annual peak sales opportunity."

But while those are promising drugs, Moderna's success for the foreseeable future will be dictated by how much of the COVID-19 market its vaccine manages to grab. That market could be worth as much as $100 billion, and right now the only approved vaccines -- from Pfizer and Moderna -- both require two doses. However, a third could soon be available, as Johnson & Johnson has requested an EUA from the FDA for its single-dose vaccine candidate. There are other companies, including Novavax, which also have vaccine candidates that could grab market share.

But right now, Moderna is ramping up production, noting that by the end of March it could hit 100 million doses. And with a price per dose of up to $37, it's easy to see how that could significantly prop up its financials. Over the past three quarters, the company has generated just $232.7 million in revenue, and that has come mainly from BARDA funding. 

It's still too early to tell how long the pandemic will drag on, and there are growing concerns that people may require annual vaccinations. Moderna is also working on booster shots for variants of COVID-19 that are emerging in various parts of the world, including South Africa and the U.K. 

There's significant sales potential for Moderna over the long term. And with a forward price-to-earnings ratio of 14, it compares well against the other healthcare stocks mentioned above:

MRNA PE Ratio (Forward) Chart

MRNA PE Ratio (Forward) data by YCharts

Moderna still looks like a promising investment. But given the uncertainty surrounding COVID-19, it likely wouldn't be suitable for risk-averse investors. 

This article represents the opinion of the writer(s), who may disagree with the "official" recommendation position of a Motley Fool premium advisory service. We're motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$52.47 (3.59%) $1.82
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$176.98 (1.75%) $3.04
Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$53.42 (-8.57%) $-5.01
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$136.25 (-4.97%) $-7.13

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.